NEW YORK (GenomeWeb) – Switzerland's CRISPR Therapeutics and Germany's Bayer today announced a yet unnamed joint venture to develop ways to deliver CRISPR/Cas9 genome editing in a clinical setting.
The deal brings together Bayer's experience in protein engineering and knowledge of human diseases with CRISPR Therapeutics' CRISPR/Cas9 intellectual property and genome editing expertise, the firms said in a statement.